At Novacea, we are fully committed to the belief that We Can™ succeed in our efforts to in-license, develop, and commercialize therapies that can potentially provide paradigm shifts in the treatment of a broad number of cancers. This commitment is evidenced by the continued advancement of our two lead oncology product candidates:
- Asentar™ (DN-101) currently in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer and a Phase 2 trial for the treatment of advanced pancreatic cancer.
- AQ4N (Banoxantrone) currently being investigated, in combination with radiation and chemotherapy, in a Phase 1/2 clinical trial in patients with newly diagnosed glioblastoma multiforme.
We have recently entered into an important strategic partnership with Schering Plough Corporation, which is designed to allow us to broaden our development platform for Asentar. This collaboration leverages Novacea’s existing capabilities with Schering-Plough’s experienced development, regulatory, and commercial teams.
Click on the links below to learn more about our leaders, business development efforts, and more.
Management/Board of Directors
Collaborations
Information Request
|
